Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

181. Breast cancer and therapy related myeloid neoplasm: systematic review

Breast cancer and therapy related myeloid neoplasm: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

182. Diagnostic value of MRI combined with ultrasound for lymph node metastasis in breast cancer: a meta-analysis

Diagnostic value of MRI combined with ultrasound for lymph node metastasis in breast cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

183. Oncometabolites of breast cancer: a systematic review

Oncometabolites of breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

184. Perinatal and obstetrical outcomes after breast cancer before pregnancy: a systematic review and meta-analysis

Perinatal and obstetrical outcomes after breast cancer before pregnancy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

185. Impact of positive margins following breast surgery for breast cancer on recurrence and survival

Impact of positive margins following breast surgery for breast cancer on recurrence and survival Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

186. The experience of patients with breast or prostate cancer recurrence: an integrative review

The experience of patients with breast or prostate cancer recurrence: an integrative review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

187. Prognostic models for predicting ovarian function in young breast cancer patients after chemotherapy: a systematic review and meta-analysis

Prognostic models for predicting ovarian function in young breast cancer patients after chemotherapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

188. Effects of yoga on life quality improvement for breast cancer patients: a meta-analysis of randomized controlled trials

Effects of yoga on life quality improvement for breast cancer patients: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

189. Interventions for radiation-induced fibrosis in patients with head and neck and breast cancer: systematic review

Interventions for radiation-induced fibrosis in patients with head and neck and breast cancer: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

190. Lifestyle interventions through participatory action research: a systematic review of alcohol and other breast cancer behavioural risk factors of diet, physical activity and smoking

Lifestyle interventions through participatory action research: a systematic review of alcohol and other breast cancer behavioural risk factors of diet, physical activity and smoking Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

191. Long non-coding RNA serve as a potential predictor biomarker for breast cancer: a systematic review and meta-analysis

Long non-coding RNA serve as a potential predictor biomarker for breast cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

192. Benefits and harms of breast cancer screening among women with a personal history of breast cancer: a systematic review and meta-analysis

Benefits and harms of breast cancer screening among women with a personal history of breast cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

193. The quality of CONSORT adverse events reporting in phase III randomized controlled trials of breast and colorectal cancers: a systematic review

The quality of CONSORT adverse events reporting in phase III randomized controlled trials of breast and colorectal cancers: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

194. Overall survival results of early detection and treatment of brain metastasis in HER2 positive breast cancer: a systematic review and meta-analysis

Overall survival results of early detection and treatment of brain metastasis in HER2 positive breast cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

195. PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis

PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

196. A systematic review of women's experiences of breast or trunk lymphoedema following treatment for breast cancer.

A systematic review of women's experiences of breast or trunk lymphoedema following treatment for breast cancer. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

197. Trastuzumab (Ogivri) - breast cancer or stomach cancer

Trastuzumab (Ogivri) - breast cancer or stomach cancer 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions 1. NAME OF THE MEDICINAL PRODUCT Ogivri 150 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One (...) for solution for infusion (powder for concentrate). White to pale yellow lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Breast cancer Metastatic breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless

2019 European Medicines Agency - EPARs

198. Pertuzumab - HER2-positive breast cancer at high risk of recurrence

Pertuzumab - HER2-positive breast cancer at high risk of recurrence Cost effectiveness of Pertuzumab (Perjeta®) for use in combination with trastuzumab and chemotherapy, for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence The NCPE has issued a recommendation regarding the cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy). Following assessment of the applicant’s submission, the NCPE recommends (...) -positive breast cancer at high risk of recurrence (defined here as patients with node-positive or hormone receptor-negative disease). The comparator is trastuzumab (in combination with chemotherapy). Final data, required by the NCPE, was received on 18th January 2019. 1. Comparative effectiveness of pertuzumab (in combination with trastuzumab and chemotherapy) Evidence was derived from the on-going phase III, randomised, double-blind, placebo- controlled APHINTY study. APHINITY evaluates pertuzumab

2019 Pediatric Endocrine Society

199. Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. (PubMed)

Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or specific tumor subtype has rarely been evaluated.To characterize breast cancer risk in relation to recent childbirth.Pooled analysis of individual-level data from 15 prospective cohort studies.The (...) international Premenopausal Breast Cancer Collaborative Group.Women younger than 55 years.During 9.6 million person-years of follow-up, 18 826 incident cases of breast cancer were diagnosed. Hazard ratios (HRs) and 95% CIs for breast cancer were calculated using Cox proportional hazards regression.Compared with nulliparous women, parous women had an HR for breast cancer that peaked about 5 years after birth (HR, 1.80 [95% CI, 1.63 to 1.99]) before decreasing to 0.77 (CI, 0.67 to 0.88) after 34 years

2018 Annals of Internal Medicine

200. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. (PubMed)

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients (...) with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy.We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles. The primary end point was invasive

2018 NEJM